James Andra H
Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Curr Opin Obstet Gynecol. 2008 Dec;20(6):550-6. doi: 10.1097/GCO.0b013e328317a427.
The purpose of this review is to summarize the epidemiology of thromboembolism in pregnancy and describe strategies to prevent and treat it.
The main reason for the increased risk of thrombosis in pregnancy is hypercoagulability. Other risk factors include a history of thrombosis, inherited and acquired thrombophilia, certain medical conditions, and complications of pregnancy and childbirth.
The hypercoagulability of pregnancy is present as early as the first trimester and so is the increased risk of thrombosis. Candidates for anticoagulation are women with a current thrombosis, a history of thrombosis, thrombophilia and a history of poor pregnancy outcome, or risk factors for postpartum thrombosis. For fetal reasons, the preferred agents for anticoagulation in pregnancy are heparins. There are no large trials of anticoagulants in pregnancy and recommendations are based on case series and the opinion of experts. Nonetheless, anticoagulants are believed to improve the outcome of pregnancy for women and their fetuses.
本综述旨在总结妊娠期血栓栓塞的流行病学情况,并描述其预防和治疗策略。
妊娠期血栓形成风险增加的主要原因是血液高凝状态。其他风险因素包括血栓形成病史、遗传性和获得性易栓症、某些疾病状况以及妊娠和分娩并发症。
妊娠期血液高凝状态早在孕早期就已出现,血栓形成风险也随之增加。抗凝治疗的适用人群包括目前患有血栓、有血栓形成病史、易栓症以及妊娠结局不良病史或产后血栓形成风险因素的女性。出于对胎儿的考虑,妊娠期抗凝治疗的首选药物是肝素。目前尚无关于妊娠期抗凝剂的大型试验,相关推荐基于病例系列研究和专家意见。尽管如此,抗凝剂被认为可改善孕妇及其胎儿的妊娠结局。